Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia.

Turčin A, Dolžan V, Porcelli S, Serretti A, Plesničar BK.

OMICS. 2016 May;20(5):283-9. doi: 10.1089/omi.2016.0003.

PMID:
27195966
2.

The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.

Plesnicar BK, Zalar B, Breskvar K, Dolzan V.

J Psychopharmacol. 2006 Nov;20(6):829-33. Epub 2006 Feb 14.

PMID:
16478753
3.

Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.

Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, Weizman A.

J Clin Psychiatry. 1997 Jul;58(7):318-22.

PMID:
9269253
4.

Polymorphisms in dopamine receptor DRD1 and DRD2 genes and psychopathological and extrapyramidal symptoms in patients on long-term antipsychotic treatment.

Dolzan V, Plesnicar BK, Serretti A, Mandelli L, Zalar B, Koprivsek J, Breskvar K.

Am J Med Genet B Neuropsychiatr Genet. 2007 Sep 5;144B(6):809-15.

PMID:
17455212
5.

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.

JAMA Psychiatry. 2015 Sep;72(9):927-34. doi: 10.1001/jamapsychiatry.2015.0891.

PMID:
26131622
6.

Relations between movement disorders and psychopathology under predominantly atypical antipsychotic treatment in adolescent patients with schizophrenia.

Gebhardt S, Härtling F, Hanke M, Theisen FM, von Georgi R, Grant P, Mittendorf M, Martin M, Fleischhaker C, Schulz E, Remschmidt H.

Eur Child Adolesc Psychiatry. 2008 Feb;17(1):44-53. Epub 2007 Sep 14.

PMID:
17876506
7.

[Prevalence of extrapyramidal effects by neuroleptics in admitted people with schizophrenia].

Moreno-Calvete MC.

Enferm Clin. 2013 May-Jun;23(3):114-7. doi: 10.1016/j.enfcli.2013.04.001. Epub 2013 Jun 5. Spanish.

PMID:
23755945
8.

Further evidence for the association between 5-HT2C receptor gene polymorphisms and extrapyramidal side effects in male schizophrenic patients.

Gunes A, Dahl ML, Spina E, Scordo MG.

Eur J Clin Pharmacol. 2008 May;64(5):477-82. doi: 10.1007/s00228-007-0450-x. Epub 2008 Jan 18.

PMID:
18205001
9.
10.

Polymorphism of dopamine D2 receptor (TaqIA, TaqIB, and-141C Ins/Del) and dopamine degradation enzyme (COMT G158A, A-278G) genes and extrapyramidal symptoms in patients with schizophrenia and bipolar disorders.

Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M, Gasso P, Deulofeu R, Mane A, Catalan R, Carne X.

Psychiatry Res. 2008 Nov 30;161(2):131-41. doi: 10.1016/j.psychres.2007.08.002. Epub 2008 Oct 15.

PMID:
18922583
11.

Relationship between adverse effects of antipsychotic treatment and dopamine D(2) receptor polymorphisms in patients with schizophrenia.

Kaiser R, Tremblay PB, Klufmöller F, Roots I, Brockmöller J.

Mol Psychiatry. 2002;7(7):695-705.

12.

Association of ADORA1 rs2228079 and ADORA2A rs5751876 Polymorphisms with Gilles de la Tourette Syndrome in the Polish Population.

Janik P, Berdyński M, Safranow K, Żekanowski C.

PLoS One. 2015 Aug 28;10(8):e0136754. doi: 10.1371/journal.pone.0136754. eCollection 2015.

13.

Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses.

Jahn T, Hubmann W, Karr M, Mohr F, Schlenker R, Heidenreich T, Cohen R, Schröder J.

Psychiatry Res. 2006 Jun 15;142(2-3):191-9. Epub 2006 May 2.

PMID:
16650902
14.

Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.

Takekita Y, Fabbri C, Kato M, Nonen S, Sakai S, Sunada N, Koshikawa Y, Wakeno M, Okugawa G, Kinoshita T, Serretti A.

Eur Arch Psychiatry Clin Neurosci. 2015 Oct;265(7):579-88. doi: 10.1007/s00406-015-0605-1. Epub 2015 May 28.

PMID:
26016467
15.

Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.

Gebhardt S, Härtling F, Hanke M, Mittendorf M, Theisen FM, Wolf-Ostermann K, Grant P, Martin M, Fleischhaker C, Schulz E, Remschmidt H.

Eur Child Adolesc Psychiatry. 2006 Oct;15(7):371-82. Epub 2006 Apr 28.

PMID:
16648965
16.

The association study of polymorphisms in DAT, DRD2, and COMT genes and acute extrapyramidal adverse effects in male schizophrenic patients treated with haloperidol.

Zivković M, Mihaljević-Peles A, Bozina N, Sagud M, Nikolac-Perkovic M, Vuksan-Cusa B, Muck-Seler D.

J Clin Psychopharmacol. 2013 Oct;33(5):593-9. doi: 10.1097/JCP.0b013e31829abec9.

PMID:
23963056
17.

No association between akathisia or Parkinsonism and suicidality in treatment-resistant Schizophrenia.

Hansen L, Jones RM, Kingdon D.

J Psychopharmacol. 2004 Sep;18(3):384-7.

PMID:
15358982
18.

Association of two DRD2 gene polymorphisms with acute and tardive antipsychotic-induced movement disorders in young Caucasian patients.

Koning JP, Vehof J, Burger H, Wilffert B, Al Hadithy A, Alizadeh B, van Harten PN, Snieder H; Genetic Risk and Outcome in Psychosis (GROUP) investigators.

Psychopharmacology (Berl). 2012 Feb;219(3):727-36. doi: 10.1007/s00213-011-2394-1. Epub 2011 Jul 13.

PMID:
21750899
19.

Acute antipyschotic efficacy and side effects in schizophrenia: association with serotonin transporter promoter genotypes.

Dolzan V, Serretti A, Mandelli L, Koprivsek J, Kastelic M, Plesnicar BK.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Aug 1;32(6):1562-6. doi: 10.1016/j.pnpbp.2008.05.022. Epub 2008 Jun 24.

PMID:
18573584
20.

Depressive symptoms in Chinese male inpatients with schizophrenia: Prevalence and clinical correlates.

Xu YM, Li F, Liu XB, Zhong BL.

Psychiatry Res. 2018 Jun;264:380-384. doi: 10.1016/j.psychres.2018.04.016. Epub 2018 Apr 5.

PMID:
29677621

Supplemental Content

Support Center